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Abstract Engineered biphasic osteochondral tissues may
have utility in cartilage defect repair. As bone-marrow-
derived mesenchymal stem/stromal cells (MSC) have the ca-
pacity to make both bone-like and cartilage-like tissues, they
are an ideal cell population for use in the manufacture of
osteochondral tissues. Effective differentiation of MSC to
bone-like and cartilage-like tissues requires two unique medi-
um formulations and this presents a challenge both in achiev-
ing initial MSC differentiation and in maintaining tissue sta-
bility when the unified osteochondral tissue is subsequently
cultured in a single medium formulation. In this proof-of-
principle study, we used an in-house fabricated microwell
platform to manufacture thousands of micropellets formed
from 166 MSC each. We then characterized the development
of bone-like and cartilage-like tissue formation in the
micropellets maintained for 8–14 days in sequential combina-
tions of osteogenic or chondrogenic induction medium. When
bone-like or cartilage-like micropellets were induced for only
8 days, they displayed significant phenotypic changes when
the osteogenic or chondrogenic inductionmedium, respective-
ly, was swapped. Based on these data, we developed an ex-
tended 14-day protocol for the pre-culture of bone-like and
cartilage-like micropellets in their respective induction medi-
um. Unified osteochondral tissues were formed by layering
12,000 osteogenic micropellets and 12,000 chondrogenic
micropellets into a biphasic structure and then further culture
in chondrogenic induction medium. The assembled tissue was
cultured for a further 8 days and characterized via histology.
The micropellets had amalgamated into a continuous structure
with distinctive bone-like and cartilage-like regions. This
proof-of-concept study demonstrates the feasibility of
micropellet assembly for the formation of osteochondral-like
tissues for possible use in osteochondral defect repair.
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Introduction
Articular cartilage has limited intrinsic regeneration capacity.
The degeneration of articular cartilage leads to osteoarthritis
(OA), which is the most common form of joint disease and
one of the leading causes of disability worldwide (Brand
et al. 2014; Chen et al. 2012; Centers for Disease Control and
Prevention 2013; Woolf and Pfleger 2003). The capacity to
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repair acute cartilage defects effectively could delay or prevent
the development of OA in many patients. A number of strate-
gies for the repair of acute cartilage defects have been proposed
which and these range from the filling of the defect with cells,
with natural/synthetic hydrogels/scaffolds, or with combina-
tions of both (Behrens et al. 2006; Brittberg et al. 1994;
Libera et al. 2006). A number of challenges are associated with
any cartilage defect repair and perhaps the most significant of
these is the effective integration of the repair tissue with the
adjacent native tissue (Archer et al. 2006; Fisher et al. 2014).
Because chondrocyte cell density is low in cartilage tissue, and
these cells have a limited capacity to migrate through cartilage
matrix at wound edges, the borders surrounding the repair tissue
are not iteratively remodeled and repair tissue is not easily
integrated with the adjacent native tissue. Additionally, the un-
derlying bone often incurs simultaneous damage during the ini-
tial injury and the building of new tissue on this damaged foun-
dation can be problematic (Muehleman et al. 2009). In proce-
dures such as mosaicplasty, the underlying bone and associated
cartilage are harvested from a donor location and transplanted
into a critical defect site (Matsusue et al. 1993). The inclusion of
the bone layer is essential as it facilitates tissue integration and
provides a foundation for the donor cartilage tissue (Huntley
et al. 2005). Whereas the bone layer rapidly and iteratively
remodels, the integration of the cartilage layer can be delayed
or even remain incomplete. A ring of dead tissue can often be
observed around the perimeter of a mosaicplasty tissue plug
(Huntley et al. 2005). Nevertheless, the inclusion of the bone
layer does indeed enhance integration and the probability of a
successful repair. A fundamental drawback in mosaicplasty is
the limited supply of autologous donor tissue available for har-
vest and the associated damage at the donor site. These limita-
tions are driving the development of tissue engineering solutions
that will enable the manufacture of either synthetic or biosyn-
thetic osteochondral tissues.
Approaches trialed in the manufacture of artificial
osteochondral tissues include the use of bilayer scaffolds, sepa-
rate scaffolds for bony and chondral layers, scaffolds for bony
layer/scaffold-free for chondral layers and single homogeneous
or heterogeneous scaffolds (Nooeaid et al. 2012). Cell-free stud-
ies have also utilized scaffolds to fill the defect site, with the
anticipation that biological Bcues^ incorporated into the scaffold
will direct host cells to repopulate the scaffold in a useful and
organized manner (Filardo et al. 2013; Filová et al. 2013;
Gotterbarm et al. 2006). This cell-free approach is probably
not suitable for large chondral defects for reasons similar to
those for the failure of mosaicplasty plugs to integrate; because
chondrocytes have a limited capacity to migrate from the dense
matrix in the adjacent native tissue, the probability that cells
would be able to populate a large scaffold is low. For this reason,
cell-free studies are often coupled with the microfracture tech-
nique, which stimulates bleeding and recruits cells from within
the underlying bone marrow (Erggelet et al. 2009; Gille et al.
2010; Siclari et al. 2012). Additionally, most scaffold ap-
proaches aim to use the scaffolds as a temporary extracellular
matrix (ECM) support and assume that the biodegradation of the
scaffold will be synchronized with the de novo tissue formation.
This synchronization is technically challenging when the scaf-
fold has multiple phases or components. Other studies have
explored the repair of full-thickness osteochondral defects with
scaffold-free approaches. However, in such cases, the repair
tissue only includes a cartilage phase (Cheuk et al. 2011;
Brehm et al. 2006) and the de novo tissue relies on the existing
bone to function as both the tissue foundation and interface.
Bone marrow-derived mesenchymal stem/stromal cells
(MSC) are frequently utilized in osteochondral defect studies
(Chen et al. 2013a, 2013b; Loken et al. 2008; Liu et al. 2006),
because these cells are assumed to have the potential to differ-
entiate into either chondrocyte- or osteoblast-like cells. The
chondrogenic or osteogenic phenotype derived fromMSC pop-
ulations is highly sensitive to the medium formulation and
chondrogenic and osteogenic media traditionally have different
formulations from each other (Pittenger et al. 1999).
Construction of a continuous osteochondral tissue in vitro pre-
sents a real challenge as it obligates the culture of both tissue
types in a single medium cocktail. Some groups have attempted
to overcome this challenge by culturing composite tissues in
custom-made double-chamber bioreactors that aim physically
to isolate each tissue type in their unique medium formulations
(Liu and Jiang 2013; Malafaya and Reis 2009). We reason that
a more rational approach might be to manufacture MSC
micropellets, to induce chondrogenic or osteogenic differentia-
tion in discrete culture systems and then to assemble the par-
tially mature micropellets into a biphasic tissue in a common
culture. Based on this rationale, we describe a method for the
high-throughput manufacture of discrete bone-like and
cartilage-like micropellets with the subsequent assembly of
the micropellets into a biphasic osteochondral-like tissue.
Bone-like and cartilage-like micropellets were manufactured
by using amodified microwell platform previously described by
our group (Markway et al. 2010; Kabiri et al. 2012). Using this
modifiedmethod, we systematically characterized the phenotyp-
ic change of bone marrow-derived MSC micropellets exposed
sequentially to osteogenic and/or chondrogenic medium.
Following the characterization and optimization of this process,
we assembled bone-like and cartilage-like micropellets into an




This study has two parts. In the first part, the phenotypic
characteristics of micropellets formed from human
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bone marrow-derived MSC cultured for 14 days under four
different sequential medium conditions are characterized. The
medium conditions are described in Table 1 and defined by the
following abbreviations: CC (chondrogenic medium for
14 days), CO (chondrogenic medium for the first 8 days and
osteogenic medium for the last 6 days), OC (osteogenic me-
dium for the first 8 days and chondrogenic medium for the last
6 days), OO (osteogenic medium for 14 days). After a 14-day
exposure to osteogenic medium and/or chondrogenic medi-
um, micropellets were assessed for DNA, chondrogenic and
osteogenic differentiation, histological features and gene ex-
pression. In the second part of the study, chondrogenic and
osteogenic micropellets are assembled at various time points
to form a continuous biphasic osteochondral-like tissue. The
biphasic tissue was assessed for cartilage and bone histologi-
cal features.
Microwell fabrication and surface modification
We used an in-house fabricated microwell surface in order to
manufacture micropellets efficiently (Babur et al. 2013). In
brief, a polystyrene microwell mold having an array of
microwells (each with dimensions of 360×360×180 μm and
600 microwells/cm2) was used to generate sheets of polydi-
methylsiloxane (PDMS, Slygard) with microwells. The pro-
cess of fabricating the mold is described in detail elsewhere
(Babur et al. 2013). Discs of 2 or 10 cm2 were punched from
the sheets of PDMS and used to make multiwell inserts with
1200 and 6000 microwells, respectively. The PDMS discs
were glued (Silicone Glue) into 24-well plates and 6-well
plates (Nunc), respectively. The plates with the microwell in-
serts were sterilized in 70 % ethanol for 1 h and then rinsed
with sterile phosphate-buffered saline (PBS, Invitrogen). To
prevent cell attachment, the surface were soaked with a 5 %
pluronic F-127 (Sigma) solution, for 5 min and then rinsed
with sterile PBS twice before cells were seeded.
Human bone marrow MSC isolation and expansion
Bone marrow aspirates were obtained from the iliac crest of
volunteer donors with written consent. This documentation is
held by the Ethics Committee and all tissue samples were
provided to the research team in a de-identified manner.
Mater Health Services approved this consent procedure.
Ethical approval for these studies was granted by the Mater
Health Services Human Research Ethics Committee (Ethics
number: 1541A) and the Queensland University of
Technology Human Research Ethics Committee in accor-
dance with the Australian National Statement on Ethical
Conduct in Human Research.
The bone marrow aspirates were processed as described
previously (Markway et al. 2010). Aspirates (∼20 ml) were
diluted 1:1 by using sterile PBS and 12 ml Ficoll Paque Plus
(GE Healthcare) was underlayed beneath the diluted aspirates.
The Ficoll and bone marrow mixture was centrifuged at 535g
for 20 min. The cells accumulated at the interface of the Ficoll
and bone marrow were aspirated carefully and washed with
sterile PBS. The cells were resuspended in low glucose
Dulbecco’s modified Eagle’s medium (LG DMEM,
Invitrogen) with 100 U/ml penicillin and 100 μg/ml strepto-
mycin (PS, Invitrogen) and 10 % fetal bovine serum (FBS,
Invitrogen), seeded in T175 flasks (Nunc) and incubated for
48 h before removal of the non-adherent cells. The plastic
adherent cells (MSC) were cultured until confluent withmedia
changes every 3–4 days, passaged at a 1:4 ratio three times
(until passage 3) and then used in micropellet studies. MSC
were expanded at 37 °C in a hypoxic incubator (2 % O2 and
5 % CO2 atmosphere) as this had been previously demonstrat-
ed to enhance proliferation and differentiation capacity
(Basciano et al. 2011; Abdollahi et al. 2011). Passage-2 ex-
panded cells were characterized for their expression of CD
marker profiles associated with MSC (Dominici et al. 2006).
Specifically, we confirmed that the cell populations used were
CD90, CD73, CD105, CD44 and CD146 positive and CD45,
CD34 and HLA-DR negative. Antibodies were purchased
fromMiltenyi Biotech and used as given in the manufacturer’s
instructions. Stained cells were analyzed on a BD LSR-II flow
cytometer.
Micropellet formation
Micropellets were formed in the multi-well plates containing
microwell inserts. In the first part of the study, 24-well plates
containing 2 cm2 microwell inserts, each containing 1200
microwells, were used. For each sample, 1 ml medium con-
taining 2×105 human MSC was dispensed to each well (166
cells/microwell) and allowed to settle for micropellet forma-
tion inside the incubator. In the second part of the study, 6-well
plates containing 10 cm2 microwell inserts, each containing
6000 microwells, were used. An aliquot of 5 ml medium
Table 1 Culture conditions defined according to media type and
culture duration: the first letter BC^ or BO^ indicates the culture
medium formulation over the first 8 days of culture and the second
letter BC^ or BO^ indicates the culture medium formulation over the
subsequent 6 days of culture. The media types were swapped at day 8
and not at day 7, because the media were changed every second day
throughout the culture period
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containing 1 million human MSC was dispensed to each well
(166 cells/microwell) and then the plates were transferred into
the incubator. Micropellet formation was confirmed via mi-
croscopy the following day.
Chondrogenic and osteogenic differentiation
Chondrogenic medium contained high glucose (HG) DMEM
with 110 μg/ml sodium pyruvate (Invitrogen), PS, 10−7 M
dexamethasone (Sigma), 200 μM ascorbic acid 2-phosphate
(Sigma), 40 μg/ml L-proline (Sigma), 1 % insulin-transferrin-
selenium-ethanolamine (ITS-X, Invitrogen) and 10 ng/ml re-
combinant human transforming growth factor-β1 (TGF-β1,
Peprotech). Cultures containing chondrogenic medium were
incubated in a 2 % O2, 5 % CO2 atmosphere at 37 °C.
Osteogenic medium contained HG DMEM (Invitrogen),
PS, 10 % FBS, 10−7 M dexamethasone, 50 μM ascorbic acid
2-phosphate and 10 mM β-glycerol phosphate (Sigma).
Cultures containing osteogenic medium were incubated in a
20 % O2, 5 % CO2 atmosphere at 37 °C.
In the first part of the study, 75 % of the medium was
exchanged every second day for 14 days except at day 8. At
day 8, 100 % of the medium was exchanged in all samples.
This was because at day 8 the medium type was switched (i.e.,
osteogenic to chondrogenic) and the cultures were placed into
different incubators at different oxygen concentrations appro-
priate for the medium type and corresponding differentiation
process.
Biphasic tissue assembly
In the second part of the study, the MSC micropellets were
differentiated in chondrogenic medium and osteogenic medi-
um separately and then assembled at various time points to
form a continuous osteochondral-like tissue. Every second
day until day 8, 75 % of the chondrogenic medium was ex-
changed and the chondrogenic micropellets were assembled
to form a macroscopic chondrogenic tissue on day 8.
Similarly, 75 % of the osteogenic medium was exchanged
every second day until day 14 and then the osteogenic
micropellets were assembled on top of the macroscopic
chondrogenic tissue to form a biphasic tissue. The assembly
of micropellets into larger tissues was achieved by using a
c u s t o m i z e d P D M S f u n n e l a n d l a y e r i n g
cylinder (see Figure S2). This device was formed by using
the tip of a 10 ml syringe (Terumo) inside a 6-well plate as a
mold to cast the PDMS. The tip of the syringe was cut and
glued to the middle of the well, the outer space left between
the syringe and the well was filled with PDMS and cured and
then the extra PDMS around the edges of the mold was re-
moved to accommodate more medium in the same well. The
mold was sterilized in 70 % ethanol for 1 h and then rinsed
repeatedly with sterile PBS prior to use for biphasic tissue
formation. On day 8, chondrogenic micropellets (12,000)
were concentrated in 2 ml medium and then transferred into
the funnel mold in two steps (1 ml each time, followed by
300g centrifugation for 2min and removal of excessmedium).
The accumulation of micropellets at the bottom of the funnel
mold was visually confirmed and the remaining portion of the
well was then filled with 5 ml chondrogenic medium.
Following the first assembly step, the assembled tissue was
cultured in a 20 % O2, 5 % CO2 atmosphere at 37 °C with
75 % of the medium volume being exchanged daily. On day
14, osteogenic micropellets (12,000) were transferred into the
funnel mold (by using the above approach) in order to gener-
ate a layer of bone tissue. Following the addition of osteogenic
micropellets, the amalgamating tissue was cultured in
chondrogenic medium for 2 more days in the funnel mold
and then gently relocated into a 6-well plate. This 6-well plate
was coated with PDMS and treated with 5 % pluronic F-127
to prevent cell attachment to the underlying tissue-culture-
treated polystyrene but otherwise had a standard geometry.
The biphasic tissue was cultured for a further 6 days in
chondrogenic medium and then characterized via histology.
Chondrogenic and osteogenic analyses
Each sample for the first part of the study consisted of 2×105
cells (initially) in the form of 1200 micropellets. DNA, sulfat-
ed glycosaminoglycan (sGAG), calcium, alkaline phospha-
tase (ALP) activity and gene expression quantifications were
performed on ∼1200 micropellets to obtain a single measure-
ment. sGAG quantification in medium was performed on
0.75 ml medium collected after each medium change on every
second day.
For DNA quantification, the micropellets were digested in
0.25 mg/ml papain (Sigma) solution at 60 °C overnight. DNA
was quantified by using PicoGreen dsDNA Reagent and Kit
(Invitrogen) according to the manufacturer’s protocol. The sig-
nal was measured by using a fluorescent plate reader (BMG
Labtech) with excitation set at 480 nm and emission at 520 nm.
The quantity of sGAG in the micropellets was measured
from the papain digests and sGAG in medium was measured
from the medium collected during culture. The medium or
digest was mixed with 1,9 dimethyl methylene blue zinc chlo-
ride double salt (DMB, Sigma) and the color change was
measured by using a plate reader (Thermo Fischer) at
590 nm. Shark chondroitin sulfate (Sigma) was used to gen-
erate a standard curve.
Calcium quantification of the micropellets was achieved by
incubating the tissues overnight in a tube shaker (Eppendorf)
at 900 rpm in 10 % acetic acid (RCI Labscan) at room tem-
perature. A 1 mg/ml o-Cresolphthalein Complexone (OCPC,
Sigma) solution was combined with 14.8-M ethanolamine-
boric acid buffer (pH 11, Sigma) and 8-hydroxyquinoline
(50 mg/ml in 95% ethanol, Merck) at a ratio of 5:5:2 and then
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diluted 10× with double-distilled (dd) H2O. The samples were
mixed with OCPC solution, incubated at room temperature for
10 min and measured by using a plate reader at 575 nm. A
standard curve was generated by using serial dilutions of pure
CaCl2 (Sigma).
ALP activity was quantified in the micropellets by first lys-
ing them in a 0.1 % Triton X-100 (Sigma) in TRIS buffer
solution (pH 10.1, Sigma) contained in a tube that was then
placed in a shaker at 900 rpm for 1 h at room temperature. The
recovered lysate was mixed with substrate solution (1 mg/ml P-
nitrophenyl phosphate disodium salt, Sigma) and incubated at
room temperature for 30 min in the dark. The absorption of the
incubated solution was measured in a plate reader at 405 nm.
Gene expression analyses
RNA was extracted from micropellets by using Trizol
(Invitrogen) as in the manufacturer’s suggested protocol. The
isolated RNA was quantified with Nanodrop 1000 (Thermo
Scientific). Reverse transcription was performed with a
SuperScript III RT and oligo(dT)20 kit (Invitrogen) as in the
manufacturer’s protocol to obtain complementary DNA
(cDNA). A Platinum SYBR Green qPCR SuperMix-UDG kit
(Invitrogen) was used to perform quantitative polymerase chain
reaction (qPCR). The primer sequences (5′ to 3′, Geneworks) in
Table S1 were used to perform the qPCR. The SYBR Green
master mix and cDNA were combined in a 384-well plate
(Applied Biosystems) by using liquid handler (epMotion M
5073, Eppendorf). The qPCR was initiated with a 2-min hold
at 50 °C, continued with a 3-min hold at 95 °C and then con-
tinued with 40 cycles of 95 °C for 15 s and 60 °C for 30 s. This
reaction was completed in a ViiA real time PCR machine
(Applied Biosystems). The gene expression was quantified by
using the ΔCt method and the relative gene expression was
calculated by normalizing the gene expression with the geo-
metric mean of two housekeeping genes (Cyclophillin A and
D-glyceraldehyde-3-phosphate dehydrogenase).
Histological analyses
The micropellets and the biphasic tissues analyzed via histol-
ogy were first fixed in 4 % paraformaldehyde (PFA, Sigma)
for 30 min to preserve the tissue structure, embedded in opti-
mum cutting temperature compound (OCT, Tissue-Tek) and
then frozen at −20 °C prior to sectioning. A cryostat (Leica)
was used at −25 °C to cut 10-μm-thick sections, which were
then placed on poly-lysine slides (Thermo Fischer), dried at
room temperature and stored at −20 °C. For staining, the sec-
tions were brought to room temperature, and to prevent de-
tachment the sections were fixed a second time onto glass
slides with 4 % PFA for 20 min and then rinsed with PBS.
Alcian blue staining was performed to identify the presence
of sGAG in the tissues. Sections were covered and incubated
for 10minwith 1%Alcian blue (Sigma) solution in 3% acetic
acid (pH 2.5). Then, the sections were rinsed with PBS and
counterstained with 4′,6 diamidino-2-phenylindole (DAPI,
Sigma) for 5 min, rinsed with PBS and mounted (CC/mount,
Sigma) for imaging.
Alizarin red staining was performed to assess osteogenic
matrix deposition. The sections were rinsed with ddH2O,
dried at 37 °C for 10 min, incubated with Alizarin Red S stain
(Sigma) for 10min, washedwith PBS and counterstainedwith
DAPI for 5 min. Finally, the sections were washed with PBS
and then mounted for imaging.
For immunofluorescence (IF) analyses, borders were
drawn around the sections with a PAP pen (Sigma). A solution
of 3 % goat serum (Invitrogen), 0.3 % Triton X-100 in 1 %
bovine serum albumin (BSA, Sigma) was used to block sec-
tions for 20 min. The sections were incubated in primary an-
tibody dilutions for human Collagen types I, II, or X (raised in
mouse, rabbit, and rabbit, respectively; Abcam) overnight at
4 °C in a humidified environment. Negative controls for col-
lagen types I, II and X were treated the same, except the
solution did not contain any primary antibody. Next day, the
primary antibody solution was washed with 0.3 % Triton X-
100 for 3 min twice and then rinsed with PBS once.
Subsequently, the corresponding secondary antibody solu-
tions (Cy-3 conjugated anti-rabbit IgG, fluorescein-
isothiocyanate-conjugated anti-mouse IgG2b, Abcam) were
added to the sections, which were then incubated for 30 min
at room temperature, washed with 0.3 % Triton X-100 for
3 min twice, counterstained with DAPI for 5 min, rinsed with
PBS and mounted for imaging.
The OsteoImage mineralization assay (Lonza) was used as in
the manufacturer’s protocol to stain the inorganic hydroxyapatite
component of bone matrix specifically. For the biphasic tissues,
the sectionswere stained and imaged. Formicropellet tissues, the
whole micropellets were stained and imaged via confocal micro-
scope. All samples were counterstained with DAPI.
Microscopy
The imaging of sections was performed by using an ECLIPSE
Ti epifluorescent microscope (Nikon, Japan) and assessed
with NIS Elements BR 3.2 software. Micropellet images and
fluorescent histology images were taken with a Nikon DS-
Qi1Mc camera, whereas color images (Alcian blue and
Alizarin red staining) were recorded by a Nikon DS-Fi1 cam-
era. The 3D images of whole micropellets stained with
OsteoImage were acquired by using a confocal microscope
(ZEISS, Germany).
Statistical analyses
The experiments were repeated with three different MSC do-
nor populations. Some differences in differentiation efficiency
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were observed between the various donors; however, the re-
lationships between the various experimental groups were re-
producible and therefore, representative data sets are present-
ed. In each experiment, each condition had n=4 biological
replicates. Data are represented in graphs as means + standard
deviation (SD). Significance analyses were performed by
using SPSS Statistics 21 (IBM, USA) and one-way analysis
of variance (ANOVA) with Tukey’s post-hoc tests. For multi-
ple comparisons, a P-value smaller than 0.05 was considered
as being significantly different. Significance is indicated with
Roman numerals, groups with same numerals being statisti-
cally similar and groups with different numerals being statis-
tically different.
Results and discussion
Flow cytometry characterization of MSC
We used MSC from four different de-identified bone-marrow
donations, which were received from a 55-year-old male, a
20-year-old male and a 23-year-old female. Two donations
from the same 55-year-old donor were collected at different
times. The CD marker expressions for donor MSC at Passage
2 are displayed in Figure S1. All MSC cultures contained
populations with <5 % positive for CD45, CD34, or HLA-
DR. All MSC cultures contained populations with >95 % pos-
itive for CD90, CD73, CD105, CD44 and CD146.
Chondrogenic and osteogenic features of micropellets
The size of the CC and OO micropellets were noticeably differ-
ent following 14 days of culture (Fig. 1a-a’’’, b–b’’’): OO
micropellets were smaller and had opaque cores. When com-
pared with OO, OC micropellets were larger and had less
opaque cores (Fig. 1a–a’’’). DNA quantification revealed that
all cultures had less DNA than the day 0 samples. However, the
cultures initiated with osteogenic medium, namely OC and OO,
had significantly less DNA than the cultures initiated with
chondrogenic medium, namely CC and CO (Fig. 1c). DNA
content is not the only factor that could have affectedmicropellet
size; the accumulation of a matrix can also vary the size of the
micropellets. In this case, however, both themicropellet size and
DNA content were lower in the OC and OO micropellets sug-
gesting that greater cell death occurred in those micropellets.
The quantity of sGAG in the micropellets and the culture
medium was measured. sGAG quantification is commonly
utilized to as an indirect measure of chondrogenesis.
Figure 1d was plotted by using the sGAG quantity found in
the medium after eachmedium exchange in order to obtain the
elution pattern of sGAG into the medium over the 2-week
culture period. The quantity of sGAG in the medium incre-
mentally increased in CC and CO micropellets, while it was
lower and constant for OC and OO micropellets over the first
8 days (Fig. 1d). Following day 8, OC and OO micropellets
continued to elute only minor quantities of sGAG into the
medium. Over the second week of the culture, sGAG elution
in COmicropellets tapered slowly at first and then significant-
ly at day 12, because of the switch to the osteogenic medium
(Fig. 1d). Figure 1e demonstrates the sGAG found in the tis-
sue on day 14 (sGAG in digest) and the accumulation of
sGAG eluted into the medium, which is the summation of
sGAG quantities found in the medium after medium ex-
changes (sGAG in media). The quantity of sGAG retained
in the micropellets was the greatest for CC, although the total
quantity of sGAG eluted into the culture medium was similar
for both the CO and CC micropellet cultures (Fig. 1e).
Figure 1f demonstrates the ratio of the total sGAG quantity
(which is the summation of sGAG in digest and total sGAG in
media) to the corresponding DNA quantity for each sample.
The sGAG/DNA ratio was the greatest for CC and CO
micropellets and lower for OC and OO micropellets
(Fig. 1f). Overall, DNA and sGAG/DNA data indicated that
the cultures initiated with a similar medium type over the first
8 days had a similar phenotype following 14 days total
culture.
In contrast to chondrogenic characterization, osteogenic
characterization provided greater resolution and indicated that
the change in medium composition did indeed influence
micropellet phenotype substantially. The calcium/DNA ratio
was the greatest for OO micropellets, being significantly low-
er for OC micropellets and was the lowest for CC and CO
micropellets (Fig. 1g). Interestingly, the ALP activity/DNA
ratio was markedly greater in the CO micropellets (Fig. 1h).
ALP activity is considered a key early indicator of osteogen-
esis being upregulated during early osteogenesis but then di-
minished as the cells continue to mature (Aubin 2001). The
Fig. 1 Morphology of micropellets, chondrogenic/osteogenic
differentiation and DNA content assessment. a–a’’’, b–b’’’ Size of the
micropellets was greatest for CC and smallest for OO micropellets. The
core of OOmicropellets appeared more opaque. Bars200 μm. cQuantity
of DNA was lower than day 0 control under all conditions and was
significantly reduced for the cultures initiated with osteogenic medium,
namely OC and OO. d Elution of sulfated glycosaminoglycan (sGAG)
into the medium was monitored throughout culture; sGAG in medium
followed an increasing pattern for micropellets initiated with
chondrogenic medium (CC, CO), whereas it was lower and steady for
OC and OOmicropellets. eQuantity of sGAG retained in the tissue at the
end of day 14 (sGAG in digest) was the greatest for CC micropellets;
however, the quantity of total sGAG eluted into the medium (sGAG in
media) was substantially greater than the quantity retained within the
micropellets. f Total sGAG/DNA ratio, which is equal to (sGAG in
digest + sGAG in media) / DNA, indicated that cultures initiated with
chondrogenic medium, namely CC and CO, were able to produce a
greater quantity of sGAG during the 2-week culture. g Calcium/DNA
ratio indicated that OO micropellets had the greatest calcium content. h
Alkaline phosphatase (ALP) activity was significantly greater only in CO
micropellets. Data represented in graphs are means + SD, n=4. Bars
200 μm
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Fig. 2 Histological assessment of micropellets. a–a’’’ Alcian blue
staining was similar for all conditions. b-b’’’ Alizarin red staining
indicated that calcification only occurred in OO micropellets. c-c’’’
collagen I staining was less intense in CC micropellets. d-d’’’
Accumulation of collagen II was lowest in OO micropellets. e-e’’’
Collagen X was present in all cultures. f-f’’’ OsteoImage, specific for
hydroxyapatite, intensely stained OO micropellets but only marked
hydroxyapatite nucleation points in OC micropellets. Bars200 μm
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elevated ALP activity observed in the COmicropellets suggests
that these tissues acquire a pre-osteogenic phenotype in re-
sponse to the change from chondrogenic to osteogenic medium.
Histological features of micropellets
Alcian blue staining indicated that all micropellets contained
sGAG, whereas a lack of Alizarin red staining indicated that
no mineralization occurred in CC or CO micropellets
(Fig. 2a–a’’’, b-b’’’). Positive Alcian blue staining of OC and
OO micropellets probably reflected the expression of sGAG
molecules commonly found in the bone (chondroitin sulfate)
and that biphasic tissue had been cultured in chondrogenic
induction medium for 8 days (Vejlens 1971; Engfeldt and
Hjerpe 1976). As expected, Alizarin red staining was the most
intense for OOmicropellets (Fig. 2b-b’’’). The presence of the
mineralized matrix in the OO micropellets was further vali-
dated with OsteoImage fluorescent stain, which is specific to
the hydroxyapatite portion of the bone matrix (Fig. 2f’’’). OC
micropellets also stained positively with OsteoImage, mark-
ing small and localized hydroxyapatite nucleation points
(Fig. 2f’’) indicating that, when the medium was changed to
the chondrogenic type, their osteogenic differentiation was
brought to a halt. Collagen II was present in CC, CO and
OC micropellets suggesting that chondrogenic medium expo-
sure was required for collagen II accumulation; therefore, OO
micropellets were stained less intensely for collagen II
(Fig. 2d-d’’’). Collagen X was present in all micropellets,
which indicated that MSC micropellets were hypertrophic,
regardless of medium type (Fig. 2e-e’’’). Collagen I was pres-
ent in CO, OC and OOmicropellets suggesting that osteogen-
ic medium exposure was necessary to trigger collagen I accu-
mulation; therefore, CCmicropellets had less intense collagen
I staining (Fig. 2c-c’’’).
Gene expression in micropellets
The gene expression for chondrogenic, hypertrophic and os-
teogenic markers (aggrecan, SOX9, collagen II and X,
versican, RUNX2, collagen I, osteocalcin, ALP and bone
morphogenetic protein 2 [BMP2]) were assessed. Aggrecan,
SOX9 and collagen II were similarly upregulated at the end of
an 8-day chondrogenesis and the expression of those genes
was further elevated following 14 days of chondrogenic dif-
ferentiation (Fig. 3a, c, e). These results indicated that chon-
drogenesis continued to progress over the full 14 days of
chondrogenic culture. SOX9 but not the chondrogenic matrix
molecules (aggrecan or collagen II), was upregulated in CO
and OC micropellets exposed to chondrogenic differentiation
medium for the first 8 days or during the last 6 days, respec-
tively. This suggested that the short-term exposure to
chondrogenic medium upregulated SOX9 expression but
was insufficient to generate a stable chondrogenic phenotype
with high collagen II expression. This paralleled a previous
report in which the lack of correlation between SOX9 and
collagen II expressions was shown in articular chondrocytes
(Aigner et al. 2003). Collagen X expression was upregulated
during the first 8-day chondrogenic culture and then remained
at a similar level in CO micropellets but increased in CC
micropellets (Fig. 3g). Versican expression was significantly
downregulated in micropellets initiated with chondrogenic
medium, namely CC and CO, when compared with day 0.
By contrast, versican expression was similar to that at day
0 at the end of culture for tissues initiated in osteogenic medi-
um, namely OC and OO (Fig. 3b). The expression of collagen
I was elevated with chondrogenic medium supplementation
(Fig. 3f). This pattern suggested that exposure to
chondrogenic medium in the culture directed collagen I ex-
pression. TGF-β1 contained in the chondrogenic medium is
known to upregulate collagen I expression specifically during
development in various tissues, including bone (Sandberg
et al. 1988; Ignotz et al. 1987; Heine et al. 1990). RUNX2
was upregulated in CO and OO conditions (Fig. 3d).
Osteocalcin, ALP and BMP2 expressions exhibited a similar
pattern, being significantly higher in CO micropellets than in
the others (Fig. 3h–j). This finding is interesting because, de-
spite the lack of calcification in CO tissues when compared
with OO, ALP activity and also gene expression for osteogen-
ic factors such as ALP, BMP2, osteocalcin and RUNX2 were
significantly elevated in COmicropellets. This parallels recent
findings (Farrell et al. 2011; Mueller et al. 2010; Scotti et al.
2010) and suggests that pre-conditioning MSC with
chondrogenic medium prior to osteogenic differentiation en-
hances bone formation by better mimicking the natural pro-
cess of endochondral ossification.
Biphasic tissue assembly and histology
Results from the first part of our study indicated that an 8-day
differentiation cycle was insufficient for MSC micropellets to
acquire the chondrogenic and osteogenic phenotypes required
for use in the assembly of a biphasic tissue. Specifically,
whereas the OC micropellets did not demonstrate
chondrogenic features after the medium was swapped, they
also did not achieve a similar state of tissue mineralization as
did the OOmicropellets. This implies that the osteogenic phe-
notype was not acquired after only 8 days in osteogenic in-
duction medium. Similarly, the CO micropellets showed
chondrogenic features after the first 8 days of culture; howev-
er, when the medium was altered from chondrogenic to oste-
ogenic, they rapidly became pre-osteogenic, parallel to previ-
ous findings (Farrell et al. 2011; Mueller et al. 2010; Scotti
et al. 2010). This result implies that the chondrogenic pheno-
type is particularly unstable and that exposure of early-stage
chondrogenic micropellets to an osteogenic medium would
result in an osteogenic phenotype. Based on these
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observations, we reasoned that the separate differentiation cul-
tures would need to be maintained for 14 days before assem-
bling the micropellets into a biphasic tissue cultured in a com-
mon medium formulation.
Our own work in this area indicates that the first phase of
discrete culture cannot be drawn out indefinitely, as the capac-
ity of cartilage micropellets to amalgamate is reduced as the
tissues mature and the matrix accumulates (Babur et al. 2013).
Similarly, more efficient fusion of human MSC conventional
pellets at earlier days of chondrogenic culture has been shown
(Bhumiratana et al. 2014). Taking these observations together,
we elected to initiate the chondrogenic and osteogenic
micropellet differentiation cultures on the same day (day 0),
assemble the chondrogenic micropellets into a cartilage-only
tissue at day 8 in chondrogenic induction medium, then layer
the osteogenic micropellets onto the cartilage tissue at day 14
and continue the biphasic tissue culture in chondrogenic in-
duction medium for an additional week (Fig. 4).
The PDMS mold used for osteochondral tissue formation
(Fig. S2) had a diameter of 4 mm and a total of 12,000
chondrogenic micropellets filled the mold to a height of 2 mm
and the same number of smaller osteogenic micropellets filled it
to an additional 0.5mm in height (Fig. 4). As the biphasic tissue
matured, the total diameter decreased slightly to ∼3 mm, al-
though the chondrogenic layer remained ∼2 mm deep and the
osteogenic layer shrunk slightly to ∼0.3 mm deep. The shrink-
age in tissue size and deviation from a perfect cylinder in tissue
morphology (Fig. 4) might have been caused by the MSC ag-
gregate Bcompaction^ phenomenon (Sart et al. 2014).
The cross-sectional area of the osteochondral tissue was
assessed for histological features of bone and cartilage.
Alcian blue stained the tissue throughout (Fig. 5a, b). This
staining highlighted individual micropellets, although discrete
micropellets were much more visible in the cartilage portion
of the tissue (Fig. 5a, b). By contrast, the Alizarin red exclu-
sively stained the bony side of the tissue; however, staining
revealed that mineralization was not always continuous
(Fig. 5c, d). In higher magnification images, individual cells
clearly bridged the two tissue layers (Fig. 5b, d).
Unexpectedly, the collagen II staining was more intense in
the bony layer relative to the chondral layer (Fig. 5e). This
differed from the first part of our study in which the
micropellets were cultured for 14 days in discreet microwells
and exhibited minimal collagen II expression in the OC me-
dium combination (Fig. 3e). This difference suggests that the
co-culture of the osteogenic and chondrogenic tissues drives
th is outcome. One poss ib le explana t ion is tha t
chondrogenically induced cells from the cartilagemicropellets
migrated onto the osteogenic-induced micropellets, forming a
layer of cells that contributed to the observed intense collagen
II staining. An alternative possibility is that paracrine signals
from the adjacent cartilage tissues modified the behavior of
the initially osteogenically induced cells, resulting in their
increased expression of collagen II. A precedent exists for a
change in cell behavior in response to the fusion of pellets and
for the signaling between adjacent fused pellets (Lehmann
et al. 2013). For example, Lehmann et al. (2013) provided
high-resolution images demonstrating that the cells that form
the layer that fuses the pellets together contribute to a unique
tissue layer with histological properties that differ from the
pellets that were fused to generate the amalgamated tissue.
Further experiments will be required to elucidate the mecha-
nism that drives the enhanced collagen II staining observed in
our osteogenic tissue layer.
Collagen X (Fig. 5f) and I (Fig. 5g) staining was present in
both layers but was more intense in the bony layer, revealing a
lower collagen content in the chondral layer; this was consis-
tent with our expectations for bone-like tissue (Farrell et al.
2011; Mueller et al. 2010; Scotti et al. 2010). The
hydroxyapatite-specific OsteoImage exclusively stained the
bony layer suggesting no accumulation of undesirable miner-
alization within the chondral layer (Fig. 5h). Our work builds
on previous work demonstrating that discreet cartilage
microtissues can be fused together to form a cartilage-like core
with a bone-like exterior (El-Serafi et al. 2011). Specifically,
our work demonstrates the possiblity of assembling cartilage-
like micropellets and bone-like micropellets to make a struc-
tured bi-phasic tissue. We believe that this capacity to assem-
ble a complex layered tissue will contribute to future efforts to
repair or regenerate articular cartilage.
Concluding remarks
Herein, we described methods for the manufacture of osteo-
genic and chondrogenic micropellets as building blocks from
bone marrow-derived MSC. Using the micropellet approach,
we first assessed the impact of various medium conditions on
osteogenic and chondrogenic differentiation of MSC. Then a
scaffold-free osteochondral tissue was assembled via layering
osteogenic and chondrogenic micropellets in a tailored culture
device. The micropellets fused into a continuous tissue
retaining the two distinct original layers. Previously, the gen-
eration of an osteochondral tissue interface by using collagen
microencapsulated rabbit MSC spheroids has been described
Fig. 3 Gene expression analysis of micropellets. Gene expression was
assessed at three different time points; day 0, day 8 and day 14. The lines
connecting time points were colored either blue for chondrogenic
medium or red for osteogenic medium (continuous blue line CC,
continuous red line OO). a, c, e, g Aggrecan, SOX9, collagen II and
collagen X were upregulated in CC micropellets. b Versican was
downregulated in chondrogenic-medium-initiated cultures. d RUNX2
was greatest in CO micropellets. f Collagen I was upregulated in CC,
CO and OC micropellets. h–j Osteocalcin, alkaline phosphatase (ALP)
and bonemorphogenetic protein 2 (BMP2) expressions were significantly
greater in COmicropellets at day 14. Data in graphs are given as means +
SD, n=4
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(Cheng et al. 2011). However, to our knowledge, this is the
first scaffold-free biphasic tissue built with a single cell type
and our results are the first to demonstrate that a continuous bi-
phasic structure can be generated without the need for a hy-
drogel or polymer support structure. In future studies, the use
of micropellets should enable the precise layering of various
Fig. 4 Biphasic tissue construction with micropellets. The monolayer-
expanded mesenchymal stem/stromal cells (MSC) were used to form
micropellets and cultured in chondrogenic medium and osteogenic
medium separately. The chondrogenic micropellets were assembled on
day 8 and then the osteogenic micropellets were layered on top at day 14
by using a custom-made polydimethylsiloxane (PDMS) mold. The
biphasic tissue was cultured for another week and then sectioned for
histological analysis
Fig. 5 Histological assessment of osteochondral-like tissue. The upper
part of the tissue is the bony layer and the lower part is the chondral layer.
a, bAlcian blue stains both the chondral and bony layers. c, dAlizarin red
specifically stains the calcified region in the bony layer. b, d At higher
magnification, the cells migrating out of the individual micropellets and
filling the void space between micropellets are visible. e, f, gCollagens II,
X, and I were all accumulated more on the bony side, although being
present on both sides. h OsteoImage stains exclusively the bony side
indicating the lack of calcification in the chondral layer. Bars200 μm
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micropellets and the more accurate replication of the complex
zonal structure found in native cartilage.
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